微信小陈
微信小章| 产品名称： | ARH-77 |
|---|---|
| 商品货号： | TS212664 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 Herpesvirus; cells contain EBV
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | plasma cell leukemia |
| Age： | 33 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： |  |
| Derivation： | The ARH-77 cell line was established from the peripheral blood of a patient suffering from IgG plasma cell leukemia.
Although established from cells taken from a patient with a plasma cell leukemia, this line has been shown to be an EBV-transformed B lymphoblastoid cell line. |
| Clinical Data： | 33 years female Caucasian |
| Antigen Expression： | CD11a +; CD19 +; CD20 +; CD28 +; CD38 -; CD49e + |
| Comments： | The cells are positive for Epstein-Barr nuclear antigen(EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). The line has been cured of a previous mycoplasma infection. LICR-LON-HMy2 (HMy2), a fast growing mutant of the ARH-77 cell line (TS212664), was irradiated and selected for class I loss to establish the HMy2.C1R (ATCC CRL-1993) cell line.xa0Subsequently, C1R-neo (ATCC CRL-2369), C1R-sB7 (ATCC CRL-2370), and C1R-B7 (ATCC CRL-2371) were established by transfection of the HMy2.C1R cell line. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 x 105 viable cells/mL andxa0maintain between 1 x 105 and 1 x 106 cells/mL. |
| Cryopreservation： | Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | D5S818: 10,13 D13S317: 11,13 D7S820: 7,12 D16S539: 9,13 vWA: 17 THO1: 8,9.3 Amelogenin: X TPOX: 8 CSF1PO: 6,10 |
| Isotype： | IgG1; kappa light chain |
| Name of Depositor： | BD Drewinko |
| Deposited As： | Homo sapiens |
| References： | Burk KH, et al. Establishment of a human plasma cell line in vitro. Cancer Res. 38: 2508-2513, 1978. PubMed: 566614 Cote RJ, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80: 2026-2030, 1983. PubMed: 6572959 Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569 Edwards PA, et al. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12: 641-648, 1982. PubMed: 7140810 Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375 Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762 Drewinko B, et al. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer 54: 1883-1892, 1984. PubMed: 6090003 |